Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. (IRON) shareholder Atlas Venture Fund X reported a proposed sale of 6,965 common shares, with an aggregate market value of $549,747.45. Merrill Lynch is listed as the broker, and the approximate sale date is October 20, 2026. The shares were acquired from Disc Medicine in a cash private placement on May 1, 2020.
Disc Medicine, Inc. (IRON) is the issuer named in a Form 144 notice for a proposed sale by Atlas Venture Fund XII of 55 common shares. The notice lists an aggregate market value of $4,341.15, an approximate sale date of October 20, 2026, Merrill Lynch as broker, and Nasdaq as the exchange. It also lists 38,392,844 issuer shares outstanding. Ommer Chohan signed the notice.
Disc Medicine, Inc. (IRON) is offering $350,000,000 of common stock and pre-funded warrants to purchase common stock, with warrants available in lieu of shares for certain investors. The warrants carry a $0.0001 per-share exercise price, do not expire, and are subject to ownership limits; they will not be listed, and no public market is expected.
The company reported positive topline results from its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X-linked protoporphyria. The trial met all primary and secondary endpoints; 183 patients were randomized to 60 mg oral bitopertin or placebo once daily for six months. Disc plans to resubmit a New Drug Application by the end of 2026, with an FDA decision anticipated by mid-2027.
Disc estimates approximately $328 million in net proceeds, for research and clinical development, potential bitopertin commercialization and general corporate purposes. Preliminary cash, cash equivalents and marketable securities were approximately $682.8 million as of September 30, 2026. Assuming the offering’s net proceeds, the company expects funding for current plans and debt service into 2030, compared with 2029 without the proceeds.
A notice concerning Disc Medicine, Inc. (IRON) lists a proposed sale by Atlas Venture Opportunity Fund II of 4,942 shares of common stock, with an approximate sale date of October 19, 2026. Merrill Lynch is named as broker, and the reported aggregate market value is $280,903.28.
Disc Medicine, Inc. (IRON) lists a proposed sale by Atlas Venture Opportunity Fund I of 5,937 common shares, with an aggregate market value of $337,459.08. The approximate sale date is October 19, 2026, through Merrill Lynch on Nasdaq. The fund acquired the shares from the issuer in a private placement on May 1, 2020. The notice lists 38,392,844 shares outstanding.
Disc Medicine, Inc. (IRON) has a Form 144 notice reporting that Atlas Venture Fund X, a shareholder, proposes to sell 14,414 common shares through Merrill Lynch. The notice lists an aggregate market value of $819,291.76 and an approximate sale date of October 19, 2026. Ommer Chohan signed the notice.
Disc Medicine, Inc. (IRON) is the issuer in a Rule 144 notice from Atlas Venture Fund XII, identified as a shareholder, proposing the sale of 115 common shares through Merrill Lynch. The notice lists October 19, 2026 as the approximate sale date and an aggregate market value of $6,536.6. Atlas Venture Fund XII acquired the shares from the issuer in a private placement on May 1, 2020, with cash payment. Ommer Chohan signed the notice.
Disc Medicine, Inc. (IRON) reported that bitopertin met both co-primary endpoints and all secondary endpoints in the APOLLO Phase 3 trial in adults and adolescents aged 12 or older with EPP or XLP. The randomized, double-blind trial enrolled 183 participants, assigned 1:1 to oral bitopertin 60 mg once daily or placebo for six months. At month six, bitopertin reduced whole-blood metal-free PPIX by 41.4% versus placebo (p<0.0001) and increased average total time in light without pain by 12.2 hours versus placebo (p=0.0010). The incidence rate of phototoxic reactions was 71% lower versus placebo.
Among adults, average daily sunlight exposure time to prodrome increased by 56 minutes versus placebo. Dizziness was reported by 50% of bitopertin recipients and 11% of placebo recipients; no participants discontinued because of adverse events. Disc plans to resubmit a New Drug Application by the end of 2026, with an FDA decision anticipated by mid-2027. Bitopertin is investigational and is not approved for use in any jurisdiction.
Disc Medicine, Inc. (IRON) reports that Chief Executive Officer and director John D. Quisel exercised options for 36,000 shares of common stock on September 15, 2026 at an exercise price of $1.01 per share. The underlying options were fully vested and exercisable, and he now directly holds 262,064 common shares and 150,120 option shares. No Rule 10b5-1 trading plan is reported for these transactions.
Disc Medicine, Inc. (symbol: IRON) is the issuer of record for a Form 4 filing submitted to the SEC.